@article{oai:niigata-u.repo.nii.ac.jp:00019890,
 author = {田島, 知郎},
 issue = {9},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Sep},
 note = {Autologous bone marrow transplantation （ABMT） was first introduced in 1979, and by the end of 1991, 61 patients with recurrent/advanced breast cancer were treated with ABMT-supported chemotherapy, and their responses appeared superior to those obtained with conventional chemotherapy. Although there have been some prolonged disease-free survivors and some of them may have been actually cured, these cases have been exceptional. It was thus felt that ABMT-supported chemotherapy should also be applied for patients with mimimum tumor residue with no prior chemotherapy. 59 patients with alleged high risk for recurrence have been enrolled in adjuvant ABMT-supported chemotherapy trial, with the longest follow-up period being 137 months. There were 23 patients who had 10 or more positive lymphnodes, and they showed 38.5% 5 year relapse-free survival（RFS）, which was in contrast to 10.0% in 30 patients treated with conventional postoperative adjuvant therapy. There were 10 patients who had been treated more than 5 years ago, and their 5 year RFS was 50.0% contrasting to 14.0% in 19 control patients. The chemotherapeutic regimen used in adjuvant was rather modest, since death is least acceptable in these situations.},
 pages = {815--820},
 title = {7）乳癌の自家骨髄移植療法(シンポジウム 自家骨髄移植の応用, 第482回新潟医学会)},
 volume = {107},
 year = {1993}
}